Skip to main content

Advertisement

SpringerLink
Log in

Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature

  • Review – Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) consist of a large heterogeneous group of epithelial tumors with neuroendocrine differentiation that arises in gastrointestinal tract and pancreatic tissues. Advanced GEP-NENs are considered distinct disease entity with limited approved treatment options and poor prognosis. So, we will explore in this systematic review the value of using bevacizumab-based combination in this subset of NENs.

Methods

PubMed, Medline, the Cochrane Library, trip database and Google Scholar were searched using the terms “GEP-NENs” OR “Gastroenteropancreatic neuroendocrine tumors” AND “systemic anticancer therapy” AND “Bevacizumab” and selecting only the English literature. Outcomes of interest included progression-free survival and overall survival (PFS and OS), tumor response and toxicities.

Results

A total of 17 potentially relevant trials were identified, of which eight studies were excluded. Hence, nine trials involving 320 patients were included. Median PFS was reported in eight out of the nine studies ranging from 8.2 to 16.5 months. Median OS was reported in one study, and it was 33.3 months for the whole group. The disease control rate was reported in the seven studies, and it ranged from 80 to 96 %. The overall response rate was reported in eight studies, and it ranged from 0 to 64 %. Frequently reported grade 3/4 toxicities were gastrointestinal toxicities, mucocutaneous toxicities and hematologic toxicities (particularly leucopenia).

Conclusions

The current evidence from the available clinical trials suggests that bevacizumab in combination with some other anticancer agents (especially mTOR inhibitors and interferons) could be a more effective and tolerable treatment for advanced GEP-NENs in the future. However, such bevacizumab-based combination cannot be recommended outside the setting of clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Aaltonen L, Hamilton S (2000) World Health Organization. Oxford, International Agency for Research on Cancer. Pathology and genetics of tumours of the digestive system. IARC Press; Oxford University Press Distributor, Lyon

    Google Scholar 

  • Abdel-Rahman O, Fouad M (2014) Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib; an updated systematic review and meta-analysis. Expert Rev Anticancer Ther [Epub ahead of print]

  • Abdel-Rahman O, Abdelwahab M, Shaker M, AbdelWahab S, Elbassiony M, Ellithy M (2013) Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol (3):655. doi:10.1007/s12032-013-0655-z. Epub 2013 Jul 4

  • Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E et al (2014) Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. BMC Cancer 14(1):184. doi:10.1186/1471-2407-14-184

    Article  PubMed Central  PubMed  Google Scholar 

  • Bosman F (2010), World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of the digestive system. (4th ed.)International Agency for Research on Cancer, Lyon

  • Brizzi MP, Berruti A, Ferrero A, Milanesi E, Volante M, Castiglione F (2009) Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer 9:388. doi:10.1186/1471-2407-9-388

    Article  PubMed Central  PubMed  Google Scholar 

  • Castellano D, Capdevila J, Sastre J, Alonso V, Llanos M, García-Carbonero R et al (2013) Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish neuroendocrine tumour group (GETNE0801). Eur J Cancer 49(18):3780–3787. doi:10.1016/j.ejca.2013.06.042 Epub 2013 Sep 5

    Article  CAS  PubMed  Google Scholar 

  • Chan JA, Mayer RJ, Jackson N et al (2013) Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumours. Cancer Chemother Pharmacol 71(5):1241–1246. doi:10.1007/s00280-013-2118-9 Epub 2013 Mar 9

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R et al (2012) Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 30(24):2963–2968. doi:10.1200/JCO.2011.40.3147 Epub 2012 Jul 9

    Article  CAS  PubMed  Google Scholar 

  • Firdaus I, Shih K, Zakari A, Lang E, McCleod M, Alguire K et al. (2012) Bevacizumab, pertuzumab, and sandostatin for patients (pts) with advanced neuroendocrine cancers (NET). J Clin Oncol 30(suppl; abstr 4127)

  • Hobday T, Qin R, Reidy D, Moore M, Strosberg J, Kaubisch A et al. Multi-center Phase II Trial of Temsirolimus (TEM) and Bevacizumab (BEV) in Pancreatic Neuroendocrine Tumor (PNET): Results of a Planned interim analysis. http://www.nanets.net/nanets_cd/2012/pdfs/C19hobdayabstract.pdf. Accessed 29 April 2014

  • Hobday T, Rubin J, Holen K et al. (2007) MC044 h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol 25(18_suppl):4504

  • Kasuya K, Nagakawa Y, Suzuki M, Suzuki Y, Kyo B, Suzuki S et al (2012) Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma. Exp Ther Med 3(4):599–602 Epub 2012 Jan 18

    CAS  PubMed Central  PubMed  Google Scholar 

  • Kloppel G (2011) Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 18(Suppl. 1):S1–S16

    Article  PubMed  Google Scholar 

  • Koumarianou A, Antoniou S, Kanakis G, Economopoulos N, Rontogianni D, Ntavatzikos A et al. (2012), Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. Endocr Relat Cancer 19(1):L1–4. doi:10.1530/ERC-11-0287. Print 2012 Feb

  • Kuiper P, Hawinkels LJ, de Jonge-Muller ES, Biemond I, Lamers CB, Verspaget HW (2011) Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 17(2):219–225. doi:10.3748/wjg.v17.i2.219

    Article  PubMed Central  PubMed  Google Scholar 

  • Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A et al (2006a) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24(3):401–406

    Article  CAS  PubMed  Google Scholar 

  • Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A et al (2006b) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24(3):401–406

    Article  CAS  PubMed  Google Scholar 

  • Lam ET, Ringel MD, Kloos RT et al (2010) Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28(14):2323–2330. doi:10.1200/JCO.2009.25.0068 Epub 2010 Apr 5

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306–1309

    Article  CAS  PubMed  Google Scholar 

  • Marton I, Knezevic F, Ramic S, Milosevic M (2012) Tomas D Immunohistochemical expression and prognostic significance of HIF-1α and VEGF-C in neuroendocrine breast cancer. Anticancer Res 32(12):5227–5232

    PubMed  Google Scholar 

  • Modlin I, Moss S, Chung D et al (2008a) Priorities for improving the management of gastroenteropancreatic neuroendocrine tumours. J Natl Cancer Inst 100:1282–1289

    Article  PubMed Central  PubMed  Google Scholar 

  • Modlin I, Oberg K, Chung D et al (2008b) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72

    Article  CAS  PubMed  Google Scholar 

  • Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10):1006–1012

    Article  PubMed  Google Scholar 

  • Oberg K, Jelic S (2009) Neuroendocrine gastroenteropancreatic tumours: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl. 4):150–153

    PubMed  Google Scholar 

  • Oberg K, Astrup L, Eriksson B et al (2004a) Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. Acta Oncol 43:626–636

    Article  PubMed  Google Scholar 

  • Oberg K, Astrup L, Eriksson B et al (2004b) Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol 43:617–625

    Article  PubMed  Google Scholar 

  • Pavel ME, Hassler G, Baum U, Hahn EG, Lohmann T, Schuppan D (2005) Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas. Clin Endocrinol (Oxf) 62(4):434–443

    Article  CAS  Google Scholar 

  • Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378(9808):2005–2012. doi:10.1016/S0140-6736(11)61742-X Epub 2011 Nov 25

    Article  CAS  PubMed  Google Scholar 

  • Pinato DJ, Tan TM, Toussi ST, Ramachandran R, Martin N, Meeran K et al (2014) An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. Br J Cancer 110(1):115–122. doi:10.1038/bjc.2013.682 Epub 2013 Nov 14

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Plockinger U, Rindi G, Arnold R et al (2004) Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80:394–424

    Article  CAS  PubMed  Google Scholar 

  • Ramage J, Davies A, Ardill J et al. (2005) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 54(Suppl. 4), pp. iv1–16

  • Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501–513. doi:10.1056/NEJMoa1003825

    Article  CAS  PubMed  Google Scholar 

  • Rinke A, Muller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663

    Article  CAS  PubMed  Google Scholar 

  • Tischer E et al (1989) Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family. Biochem Biophys Res Commun 165:1198–1206

    Article  CAS  PubMed  Google Scholar 

  • Varker KA, Campbell J, Shah MH (2008) Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol 61(4):661–668 Epub 2007 Jun 23

    Article  CAS  PubMed  Google Scholar 

  • Volante M, Righi L, Berruti A et al (2011) The pathological diagnosis of neuroendocrine tumours: common questions and tentative answers. Virchows Arch 458:393–402

    Article  CAS  PubMed  Google Scholar 

  • Yao J, Phan A, Hess K, Fogelman D, Jacobs C, Dagohoy C et al. Randomized run-in study of Bevacizumab and Everolimus in low- to intermediate- grade neuroendocrine tumor (LGNETs) using perfusion CT (pCT) as functional biomarker. http://www.nanets.net/nanets_cd/2010/pdfs/C36.pdf. Accessed 29 April 2014

  • Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC et al (2008) Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26(8):1316–1323. doi:10.1200/JCO.2007.13.6374

    Article  CAS  PubMed  Google Scholar 

  • Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523. doi:10.1056/NEJMoa1009290

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

We have no conflicts of interest.

Author information

Authors and Affiliations

  1. Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lotfy Elsayed Street, 11665, Cairo, Egypt

    Omar Abdel-Rahman

  2. Medical Microbiology and Immunology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    Mona Fouad

Authors
  1. Omar Abdel-Rahman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mona Fouad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Omar Abdel-Rahman.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abdel-Rahman, O., Fouad, M. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature. J Cancer Res Clin Oncol 141, 295–305 (2015). https://doi.org/10.1007/s00432-014-1757-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-014-1757-5

Keywords

Search

Navigation